Skip to main content

ADVERTISEMENT

Ghassan Abou-Alfa, MD, MBA

Dr Abou-Alfa
CIO2022 Highlights
09/30/2022
Dr Abou-Alfa discusses his CIO2022 abstract, "Transarterial Chemoembolization ± (Tremelimumab and Durvalumab ± Lenvatinib) in Hepatocellular Carcinoma: EMERALD-3."
Dr Abou-Alfa discusses his CIO2022 abstract, "Transarterial Chemoembolization ± (Tremelimumab and Durvalumab ± Lenvatinib) in Hepatocellular Carcinoma: EMERALD-3."
Dr Abou-Alfa discusses his...
09/30/2022
IO Learning